Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
WisdomTree AUM totals $168.93 billion as of Sept. 30, 2026

WisdomTree AUM totals $168.93 billion as of Sept. 30, 2026

BitgetBitget2026/10/12 10:01
  • WisdomTree reported total AUM of $168.93 billion as of Sept. 30, 2026, down from $173.65 billion at the start of September.
  • September net inflows totaled $1.19 billion; year-to-date net inflows reached $13.54 billion, a 12.7% annualized flow rate.
  • Market moves reduced AUM by $5.92 billion in September; year-to-date market gains added $8.65 billion.
  • Acquired AUM contributed $4.1 billion year-to-date; blended total average fee rate held at 36 bps.
  • Tokenized AUM approached $1.3 billion, up 65% year-to-date; a broader planned product rollout was flagged.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. WisdomTree Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261012941571) on October 12, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks